Intra-Cellular Therapies Inc (ITCI)
64.96
-0.57
(-0.87%)
USD |
NASDAQ |
May 10, 16:00
64.96
0.00 (0.00%)
After-Hours: 20:00
Intra-Cellular Therapies Gross Profit Margin (Quarterly): 93.16% for March 31, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 93.16% |
| December 31, 2023 | 91.86% |
| September 30, 2023 | 92.74% |
| June 30, 2023 | 93.50% |
| March 31, 2023 | 92.87% |
| December 31, 2022 | 92.24% |
| September 30, 2022 | 91.86% |
| June 30, 2022 | 91.56% |
| March 31, 2022 | 90.92% |
| Date | Value |
|---|---|
| December 31, 2021 | 90.05% |
| September 30, 2021 | 90.74% |
| June 30, 2021 | 89.27% |
| March 31, 2021 | 90.66% |
| December 31, 2020 | 90.80% |
| September 30, 2020 | 92.45% |
| June 30, 2020 | 93.15% |
| March 31, 2020 | 92.15% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
89.27%
Minimum
Jun 2021
93.50%
Maximum
Jun 2023
91.76%
Average
91.86%
Median
Dec 2023
Gross Profit Margin (Quarterly) Benchmarks
| Johnson & Johnson | 69.55% |
| Insmed Inc | 77.96% |
| Vertex Pharmaceuticals Inc | 87.27% |
| Fate Therapeutics Inc | -- |
| ADMA Biologics Inc | 42.06% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -18.32% |
| Return on Assets | -15.28% |
| Return on Invested Capital | -18.32% |
| Profit Margin (Quarterly) | -10.53% |
| Operating Margin (Quarterly) | -14.47% |
| Return on Net Operating Assets | -74.78% |